CVD Risk Prediction: Basic Concepts, Current Status, and Future Directions Donald M. Lloyd-Jones MD ScM FACC FAHA Chair and Associate Professor Department.
Management of Hyperlipidemia Clinical Management Course 1/30/06 James M. May, M.D. Department of Medicine Vanderbilt University School of Medicine.
Robyn McDermott MBBS, FAFPHM, MPH, PhD. Director CCDP, JCU Cairns
The REVERSAL Trial Reversing Atherosclerosis With Aggressive Lipid Lowering.
Endothelial Dysfunction as a Marker of Cardiovascular Events Robert A. Vogel, M.D.
The grey zone: What to do for the “intermediate risk” patient?
Lipids and Cardiovascular Disease Prevention Epidemiology Clinical Trials Evidence Dietary and Pharmacologic Management Nathan Wong.
Genes for CV prediction & treatment: Fact or Fiction? Prof. Steve Humphries University College London.
Global Cardiac Risk Management Anthony Battad CD, MD, MSc., MPH, FRCPC Director // Directeur Ambulatory Care, St. Boniface Hospital // Soins ambulatoire,
EBP Step 2: Rapid Access to the best evidence
Genes for CV prediction & treatment: Fact or Fiction?